Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Spine Market Leade | Globus Medical, an $8 billion spine and orthopedics powerhouse, faces challenges while pursuing strategic growth in robotics and emerging technologies |
Financial Resilience | Despite Q1 2025 setbacks, Globus maintains 2025 guidance. Analysts project EPS of $3.10-$3.40, with an average price target of $100 |
Strategic Acquisitions | Explore Globus Medical's expansion into neuromodulation with Nevro Corp acquisition and the successful integration of NuVasive merge |
Innovation Drive | Delve into Globus Medical's robust product pipeline, including 18 new launches in 2024 and record-breaking performance in Emerging Technology segment |
Metrics to compare | GMED | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGMEDPeersSector | |
---|---|---|---|---|
P/E Ratio | 43.0x | −13.2x | −0.5x | |
PEG Ratio | 0.30 | 0.16 | 0.00 | |
Price/Book | 2.0x | 3.0x | 2.6x | |
Price / LTM Sales | 3.2x | 2.6x | 3.1x | |
Upside (Analyst Target) | 31.2% | 59.2% | 50.4% | |
Fair Value Upside | Unlock | −3.0% | 8.7% | Unlock |